Form 4: Recursion Pharmaceuticals CEO Christopher Gibson Reports Stock Sales and Conversions

Christopher Gibson, CEO of Recursion Pharmaceuticals, reported the sale of Class A Common Stock and the conversion of Class B Common Stock into Class A Common Stock, according to a recent SEC Form 4 filing.

Summary

• On May 1, 2024, Christopher Gibson, CEO of Recursion Pharmaceuticals, sold 25,000 shares of Class A Common Stock at $0 and 50,000 shares at $7.73.
• On May 2, 2024, he sold 28,704 shares of Class A Common Stock at $8.47 and 21,296 shares at $8.47.
• Also on May 2, 2024, 21,296 shares of Class B Common Stock were converted into Class A Common Stock due to a bona-fide gift of shares.
• Following these transactions, Gibson directly owns 834,820 shares of Class A Common Stock.
• He also indirectly owns shares through LAHWRAN-3 LLC (486,000 shares), LAHWRAN-4 LLC (388,000 shares), and the Gibson Family Trust (67,875 shares).
• Gibson holds options to purchase a total of 1,997,436 shares of Class A Common Stock at various exercise prices and vesting schedules.

Sentiment

Score: 5

Explanation: Neutral sentiment. The filing simply reports transactions and doesn't inherently indicate positive or negative news. The CEO selling shares could be seen as slightly negative, but the existence of a 10b5-1 plan mitigates this concern.

Negatives

• The CEO's sale of shares could be interpreted negatively by some investors.

Risks

• Continued sales of shares by insiders could put downward pressure on the stock price.

Industry Context

Insider trading activity is always closely watched by investors as it can provide insights into management's view of the company's prospects. Rule 10b5-1 plans are often used to schedule trades in advance to avoid accusations of trading on inside information.

Comparison to Industry Standards

• It's common for CEOs of publicly traded companies, including those in the biotechnology sector like Recursion Pharmaceuticals, to have compensation packages that include stock options and restricted stock units.
• These equity-based awards are designed to align the interests of management with those of shareholders.
• The vesting schedules and exercise prices of Gibson's stock options are typical for executive compensation packages in the industry.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize similar equity compensation strategies for their executives.

Stakeholder Impact

• Shareholders may react to the reported stock sales, potentially influencing the stock price.
• The transactions do not appear to directly impact employees, customers, suppliers, or creditors.

Key Dates